Common questions
Which tirzepatide program tops the 2026 list?
On our rubric, MaxLife lands at #1 among the 10 programs, mostly for flat all-in tirzepatide pricing with no membership (from $195/mo, $150/mo on a 12-month plan) and named pharmacy partners. Mochi ranks high for included video visits and a registered dietitian; Ivim for its low tirzepatide entry price; Henry Meds for oral tirzepatide formats. Verify current details on each provider's own site.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness, or quality. It is prepared by U.S.-licensed compounding pharmacies when a licensed provider determines treatment is appropriate. Compounded tirzepatide is not Mounjaro® or Zepbound®.
Why does pharmacy transparency matter for compounded tirzepatide?
Because compounded tirzepatide is not FDA-approved, the compounding pharmacy is the primary quality signal. Programs that name their pharmacy partner and can supply a certificate of analysis (potency, sterility) give patients a way to verify what they're injecting. Several programs in this countdown don't publicly name their current pharmacy.
How much does compounded tirzepatide cost per month?
Among the programs here, compounded tirzepatide runs from roughly $133 to $549 per month, though several add a separate membership fee (Mochi, Ivim, Zealthy), gate exact pricing behind an intake form (Henry Meds), or tier it by dose (Willow, Emerge). MaxLife starts at $195/mo and drops to $150/mo on a 12-month plan. Figures were sourced in mid-2026 and change frequently; confirm current pricing on each program's own site.
Is compounded tirzepatide still legal in 2026?
It's far more restricted than it was. After the FDA declared the tirzepatide shortage resolved in 2025, the broad shortage-era window that let pharmacies compound tirzepatide for cost or convenience closed. Compounding is now generally limited to a narrow, documented individual medical need that a licensed prescriber signs off on — for example, a verified allergy to an inactive ingredient in the branded product — not routine savings or preference. The FDA also warned telehealth marketers in 2025, and compounded tirzepatide remains not FDA-approved. This is general information, not legal or medical advice.
Compounded tirzepatide vs. Zepbound® — is it the same medication?
They share the same active ingredient, tirzepatide, but they aren't interchangeable. Zepbound® is FDA-approved and made under manufacturer oversight; compounded tirzepatide is not FDA-approved and carries no such assurance. Cash-pay compounded tirzepatide is usually cheaper up front, but with insurance or a manufacturer savings offer the brand can end up cheaper — and it comes with the FDA review that compounded versions lack. Discuss the trade-offs with a licensed clinician.
How is tirzepatide dosed and titrated?
Tirzepatide is typically started low — around 2.5 mg once weekly — and stepped up gradually, commonly every four weeks, toward a maintenance dose of up to 15 mg weekly. The slow titration is deliberate: easing the dose up helps limit gastrointestinal side effects, and it means you shouldn't expect the full effect in the first few weeks. Dosing should always happen under a prescriber's guidance. See our tirzepatide dosing guide for more detail.
Can I switch from compounded tirzepatide to Zepbound®?
Often, yes. Because it's the same molecule, Zepbound® uses the same milligram doses and the same titration ladder, so a clinician can usually manage the transition without starting over. With brand coverage expanding, it can also be worth re-checking your insurance and any prior-authorization requirements before you switch. Make any change under a prescriber's supervision rather than on your own.
Is oral or sublingual tirzepatide as effective as the injection?
That isn't established. Oral, sublingual, and so-called microdose compounded tirzepatide formats haven't been well studied in people, so how much is actually absorbed and how well they work are open questions. The injectable form has far more real-world track record behind it. Treat non-injectable formats with extra caution and ask any provider what evidence supports the specific product they're selling. Compounded tirzepatide is not FDA-approved.
What are the common tirzepatide side effects?
The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — and they tend to be strongest when you first start or increase the dose, which is part of why slow titration helps. Tirzepatide also carries a boxed warning about thyroid C-cell tumors seen in rodent studies. Discuss your personal risks with a licensed clinician; individual results and tolerability vary.
MLMaxLifeCompounded tirzepatide · all 50 states
Mo
Tr
Ed
iv
H
Z
W
Fe
Em